ClinicalTrials.gg

Hemoglobinuria, Paroxysmal clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 191 studies for Hemoglobinuria, Paroxysmal across more than 10 countries. 49 are recruiting or about to start. 156 of them are mainly about Hemoglobinuria, Paroxysmal (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-16.

Status

Completed
103
Recruiting
30
Active, not recruiting
19
Not yet recruiting
15
Terminated
13
Status unknown
5

Phase

Phase 2
70
Phase 3
50
Phase 1
29
Phase 4
3

Where

United States
68
China
51
United Kingdom
45
Italy
33
Korea, Republic of
33
France
28

Who develops what

Add Hemoglobinuria, Paroxysmal to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 22 programs from 18 companies, 22 with this as their studies’ main aim; 7 with a live phase 3 study; 8 primary completions in the next 12 months. Compare Regeneron Pharmaceuticals, Fosun Pharma and Haisco Pharmaceutical Group here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
eculizumabRecent, repeated
Evidence
  • NCT07816237 · Bisirna Therapeutics (Suzhou) Co., Ltd. · Phase 3 · live · comparator · “Eculizumab (Soliris®)” · registered Sep 2026
  • NCT07747090 · Fosun Pharma · Phase 3 · live · comparator · “Eculizumab infusion” · registered Jul 2026
  • NCT07177859 · Sino Biopharmaceutical Limited · Phase 3 · live · comparator · “Eculizumab Injection” · registered Sep 2025
  • NCT06932744 · Wuhan Createrna Science and Technology Co., Ltd · Phase 3 · live · comparator · “Eculizumab Injection” · registered Apr 2025
  • NCT05646563 · NovelMed Therapeutics · Phase 2 · live · background · “Soliris” · registered Nov 2022
AstraZeneca82% of its industry studiesUS: AstraZeneca (FDA 2007) + 2 othersEU: AstraZeneca (EMA 2007) + 2 others55 studies

1 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
NTQ5082☆ Track2 live phase-3 studies: NCT07177859, NCT07177872Sino Biopharmaceutical Limited
lanoracopan☆ Track3 live phase-3 studies: NCT06932744, NCT06932471, NCT06933914Wuhan Createrna Science and Technology Co., Ltd
VSA012☆ Track1 live phase-3 study: NCT07816237Bisirna Therapeutics (Suzhou) Co., Ltd.
iptacopanApproved: US 2023 · EU 2024☆ Track2 live phase-3 studies: NCT04747613, NCT06934967Novartis
FXS6837☆ Track2 live phase-3 studies: NCT07914894, NCT07747090Fosun Pharma

The 5 in phase 3 with the nearest primary completion, of 22 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (8)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • Nov 2026 est.NTQ5082 · Sino Biopharmaceutical Limited · Phase 3 main aim+ NTQ5082 vs eculizumabNCT07177859 A Phase III Study of NTQ5082 Capsules in the Treatment of Paroxysmal Nocturnal Hemoglobinuria Patients — primary endpoint: Proportion of subjects with hemoglobin (HB) levels ≥120 g/L on at least three of the four measurements between Weeks 18 and 24 in the absence of red blood cell (RBC) transfusions (defined as no RBC transfusions after Week 2 (D15) until Week 24 (D169)) · 78 enrolled
  • 30 Dec 2026 est.lanoracopan · Wuhan Createrna Science and Technology Co., Ltd · Phase 3 main aimNCT06933914 Long-term Safety and Tolerability of MY008211A Tablets in Patients With Paroxysmal Nocturnal Hemoglobinuria — primary endpoint: Proportion of participants with adverse events, safety laboratory parameters, vital signs, ECG. · 120 enrolled
  • 30 May 2027 est.HS-10542 · Hansoh Pharmaceutical Group Company Limited · Phase 2 main aimNCT07470762 Study of Safety and Efficacy of HS-10542 in Patients With Paroxysmal Nocturnal Hemoglobinuria — primary endpoint: Phase 1b: Incidence and severity of adverse events · 50 enrolled

5 more — sign in to see them all, free.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Hemoglobinuria, Paroxysmal studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Alkylating agents 2 open · Antimetabolites 6

Coming up

19studies finish main data collection within a year6 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 30 Hemoglobinuria, Paroxysmal studies recruiting now, 14 (47%) set no upper age limit and 12 (40%) stop at 75 or younger. 12 (40%) take children under 18. 1 (3%) are for women only and 0 (0%) for men only; 4 (13%) take healthy volunteers.

Recruiting studies that take each age, of 30
AgeWomenMen
1010 (33%)9 (30%)
1828 (93%)27 (90%)
3027 (90%)26 (87%)
4027 (90%)26 (87%)
5026 (87%)25 (83%)
6525 (83%)24 (80%)
7523 (77%)22 (73%)
8516 (53%)15 (50%)

Across all 191 studies, recruiting or not: 32% stop at 75 or younger and 18% at 65; 25% take children; 1% are for women only and 1% for men only; 11% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Hemoglobinuria, Paroxysmal studies take

Of 35 phase 3 interventional studies under Hemoglobinuria, Paroxysmal, half reached primary completion within 23 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 113 mo5–34 · 19 studies——
Phase 224 mo12–80 · 34 studies16 mo11–25 · 26 studies—
Phase 323 mo15–41 · 35 studies23 mo15–41 · 35 studies—
Observational42 mo24–245 · 23 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 191. Browse all 191 → or search them.